mecasermin mecasermin mecasermin, sold under the brand name increlex, also known as recombinant human insulin-like growth factor-1 (rhigf-1), is a recombinant form of human insulin-like growth factor 1 (igf-i) which is used in the long-term treatment of growth failure and short stature in children with severe primary igf-i deficiency, for instance due to growth hormone deficiency or laron syndrome (growth hormone insensitivity). mecaserminclinical datatrade namesincrelexother namesfk-780; recombinant human insulin-like growth factor-1; rhigf-1; somatomedin-1ahfs/drugs.commonographlicense data eu ema: by inn pregnancycategory au: b3 routes ofadministrationsubcutaneous injectionatc codeh01ac03 (who) legal statuslegal status au: s4 (prescription only) ca: rx-only / schedule d us: ℞-only pharmacokinetic dataelimination half-life5.8 hoursidentifierscas number68562-41-4 ndrugbankdb01277 nchemspidernoneunii7gr9i2683okeggd04870 nchemblchembl1201716 nchemical and physical dataformulac331h512n94o101s7molar mass7648.71 g·mol−1 ny (what is this?) (verify) mecasermin has a biological half-life of about 5.8 hours in children with severe primary igf-1 deficiency. a related medication is mecasermin rinfabate (brand name iplex), which is a combination of mecasermin (rhigf-1), insulin-like growth factor binding protein-3 (igfbp-3), and insulin-like growth factor binding protein acid labile subunit (igfals) as a ternary complex. the complex serves to prolong the action of mecasermin in the human body; the half-life of mecasermin when provided as this complex is 13.4 hours in individuals with severe primary igf-1 deficiency.